Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
150 participants
INTERVENTIONAL
2016-11-30
2017-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A - mucolytic solution
Mucolytic solution consisting of 100 ml of water, 100 mg of simethicon and 400 mg of N-acetylcystein administered 30 minutes prior to upper endoscopy.
Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)
B - no intervention
Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
No interventions assigned to this group
C - water
100 ml of water given 30 minutes prior to upper endoscopy.
Administration of water before upper endoscopy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)
Administration of water before upper endoscopy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed informed consent
* diagnostic gastroscopy
Exclusion Criteria
* interventional gastroscopy
* known disease of the upper GI tract and/or history of surgery of GI tract
* gastroscopy indicated of bleeding, dysphagia or ileus
* liver cirrhosis
* general anesthesia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vitkovice Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Premysl Falt, M.D., Ph.D.
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Premysl Falt, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Digestive Diseases Center, Vítkovice Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Digestive Diseases Center
Ostrava, , Czechia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Premysl Falt, M.D., Ph.D.
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Stepan M, Falt P, Pipek B, Fojtik P, Hanousek M, Hill M, Urban O. Administration of mucolytic solution before upper endoscopy - double-blind, monocentric, randomized study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023 Mar;167(1):69-73. doi: 10.5507/bp.2021.038. Epub 2021 Jun 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DDC VN 09
Identifier Type: -
Identifier Source: org_study_id